Psybio Therapeutics Corp Stock Price To Sales
| PSYBF Stock | USD 0.0001 0.00 0.00% |
PsyBio Therapeutics Corp fundamentals help investors to digest information that contributes to PsyBio Therapeutics' financial success or failures. It also enables traders to predict the movement of PsyBio Pink Sheet. The fundamental analysis module provides a way to measure PsyBio Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PsyBio Therapeutics pink sheet.
PsyBio |
PsyBio Therapeutics Corp Company Price To Sales Analysis
PsyBio Therapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, PsyBio Therapeutics Corp has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
PsyBio Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PsyBio Therapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PsyBio Therapeutics could also be used in its relative valuation, which is a method of valuing PsyBio Therapeutics by comparing valuation metrics of similar companies.PsyBio Therapeutics is currently under evaluation in price to sales category among its peers.
PsyBio Fundamentals
| Return On Equity | -3.1 | |||
| Return On Asset | -0.98 | |||
| Current Valuation | 3.69 M | |||
| Shares Outstanding | 80.85 M | |||
| Shares Owned By Insiders | 25.61 % | |||
| Shares Owned By Institutions | 13.23 % | |||
| Price To Book | 202.42 X | |||
| Gross Profit | (1.56 M) | |||
| EBITDA | (10.91 M) | |||
| Net Income | (11.02 M) | |||
| Cash And Equivalents | 911.83 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 207.81 K | |||
| Debt To Equity | 7.03 % | |||
| Current Ratio | 0.89 X | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (6.95 M) | |||
| Earnings Per Share | (0.09) X | |||
| Market Capitalization | 4.94 M | |||
| Total Asset | 4.01 M | |||
| Z Score | 7.2 | |||
| Net Asset | 4.01 M |
About PsyBio Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PsyBio Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PsyBio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PsyBio Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in PsyBio Pink Sheet
PsyBio Therapeutics financial ratios help investors to determine whether PsyBio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PsyBio with respect to the benefits of owning PsyBio Therapeutics security.